- A First-in-Class Breakthrough Transdermal Collagen Gel Serum
New Delhi, India: ENTOD Pharmaceuticals today announced the launch of COLLADERM™️, a global breakthrough in regenerative skincare. Officially unveiled at the 54th National Conference of the Indian Association of Dermatologists, Venereologists & Leprologists (DERMACON 2026), COLLADERM™️ introduces a first-in-class transdermal collagen gel serum designed for deep, structural skin regeneration. The product is now officially available in the market from February onwards.
Developed in the UK using advanced AI-driven bio-engineering and exclusively licensed to ENTOD Pharmaceuticals for the Indian market, the COLLADERM™️formulation has been further optimised at ENTOD’s DSIR-approved R&D center in India. The product has been refined to address Indian skin biology, climatic conditions, and real-world clinical requirements.
Collagen plays a central role in skin resilience, hydration, elasticity, and visible firmness. However, conventional collagen formats face practical limitations: injectable options are procedure-based and costly, oral collagen absorption can be inconsistent, and topical collagen often struggles to penetrate beyond the skin surface. COLLADERM™️ is engineered to overcome these barriers through advanced collagen bio-engineering and transdermal delivery science, supporting visible skin renewal, enhanced hydration, improved firmness, and a rejuvenated appearance.
Speaking on the launch, Mr. Nikkhil K. Masurkar, CEO of ENTOD Pharmaceuticals, said “COLLADERM™️reflects ENTOD’s commitment to translating world-class science into dermatologist-led skincare. While collagen is essential for youthful, resilient skin, many existing formats fail to deliver meaningful benefits beyond the surface. With COLLADERM™️, we have combined AI bio-engineered collagen with advanced transdermal delivery to enable deeper hydration, improved firmness, and visible skin rejuvenation, setting a new benchmark in regenerative skincare.”
At the core of COLLADERM™️ is ENTOD’s proprietary Quattro Collagen System, which integrates Type III and Type XVII Recombinant Vegan Collagens (RVC), previously unavailable in India, in both high and low molecular weights for multi-depth biological action. This system is supported by TRANSCELLAR™️, a cold-processed transdermal liposomal delivery platform engineered to enhance penetration and cellular uptake. The formulation is further enriched with hyaluronic acid, glycerin, and vitamin C, supporting hydration, permeability, and collagen co-activation.
Commenting on the clinical relevance, Dr Jijith KR, Director & Chief Dermatologist, COSMALIFE Skin Clinic, Bangalore, said “Collagen is fundamental to maintaining skin structure, elasticity, hydration, and a youthful appearance, yet many topical products fail to deliver meaningful outcomes due to poor
penetration. Advanced collagen systems combined with enhanced delivery technologies can significantly improve clinical performance. COLLADERM™️ represents a promising evolution in regenerative skincare, supporting improved hydration, smoother texture, and visibly refreshed skin. For patients seeking dermatologist-guided, science-driven skincare, this offers a sophisticated and modern collagen solution.”
Manufactured in India under the ‘Make in India’ initiative at an internationally accredited facility through an India–UK technology transfer collaboration, COLLADERM™️ reinforces ENTOD’s expanding footprint in dermatology-led innovation and advanced skincare science.
COLLADERM™️ will be available exclusively through specialist dermatologist clinics and positioned as a prescription-led, science-first regenerative gel serum.
With over 48 years of scientific excellence, ENTOD continues to expand its research-driven portfolio across specialty healthcare, integrating deep medical research with next-generation formulation engineering.
About ENTOD Pharmaceuticals
ENTOD Pharmaceuticals is a global, research-driven pharmaceutical company with over 48 years of expertise across Ophthalmology, ENT, and Dermatology. With 300+ formulations, a 2,000+ strong global workforce, and presence in 67 countries, ENTOD operates to the highest international GMP and European quality standards, delivering innovation-driven healthcare solutions worldwide.
